15 completed, 4 unknown, 3 active not recruiting, 3 recruiting. 26 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 15, Unknown 4, Active not recruiting 3, Recruiting 3, Terminated 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
Follow dacomitinib: new trials by email Literature Review of dacomitinib trials Research Report on dacomitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations Dacomitinib+Anlotinib, Dacomitinib - Non-Small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Recruiting | Shanghai Chest Hospital | 140 | 2022-10-13 | 2023-04-19 |
| Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers Oral Dacomitinib - Advanced Solid Tumours, Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | National Cancer Centre, Singapore | 24 | 2021-08-24 | 2025-06-11 |
| Dacomitinib in Lung Cancer With Uncommon EGFR Mutations Dacomitinib - Non-small Cell Lung Cancer Metastatic, EGF-R Positive Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | Shanghai Chest Hospital | 30 | 2020-12-08 | 2025-09-08 |
| Central Nervous System(CNS) Efficacy of Dacomitinib Dacomitinib - Non Small Cell Lung Cancer, Brain Metastases | Phase 2 | Unknown | Samsung Medical Center | 30 | 2020-12-07 | 2021-01-05 |
| PLATFORM Study of Precision Medicine for Rare Tumors Almonertinib 110 MG, Dacomitinib 45 MG, Alectinib 150 MG - Rare Tumor | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 770 | 2020-08-15 | 2025-02-11 |
| An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Dacomitinib - Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases | Phase 2 | Unknown | Guangdong Association of Clinical Trials | 50 | 2020-08-01 | 2020-04-09 |
| Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations Osimertinib, Dacomitinib - NSCLC | Phase 2 | Unknown | Fondazione Ricerca Traslazionale | 170 | 2020-06-12 | 2023-02-21 |
| Phase 2 Study of Dacomitinib in NSCLC Dacomitinib - NSCLC Stage IIIB, NSCLC Stage IIIC | Phase 2 | Active not recruiting | National Cancer Centre, Singapore | 118 | 2019-09-11 | 2025-06-12 |
| The Drug Rediscovery Protocol (DRUP Trial) Panitumumab, Olaparib, Dabrafenib - Cancer, Tumors | Phase 2 | Recruiting | The Netherlands Cancer Institute | 1550 | 2016-08-01 | 2024-01-24 |
| A Rollover Protocol of Dacomitinib For Patients In Japan Dacomitinib - NSCLC | Phase 2 | Completed | Pfizer | 7 | 2015-07-10 | 2020-07-02 |
| Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer Dacomitinib - Skin Squamous Cell Cancer | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 43 | 2014-11-01 | 2016-07-04 |
| Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC Dacomitinib, PD-0325901, Docetaxel - Colorectal Cancer | Phase 1 / Phase 2 | Completed | The Netherlands Cancer Institute | 35 | 2014-04-02 | 2025-07-08 |
| A Phase II Study of Dacomitinib in Progressive Brain Metastases Dacomitinib - Brain Cancer | Phase 2 | Terminated | David Piccioni, M.D., Ph.D | 4 | 2014-02-01 | 2016-09-22 |
| A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer Dacomitinib - Non-small Cell Lung Cancer | Phase 2 | Completed | Pfizer | 41 | 2013-07-01 | 2017-07-18 |
| Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis Dacomitinib - Penile Neoplasms, Carcinoma, Squamous Cell | Phase 2 | Completed | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 32 | 2013-06-15 | 2021-05-14 |
| Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT. PF-299804 (Dacomitinib) - Glioblastoma, Brain Tumor, Recurrent | Phase 2 | Completed | Grupo Español de Investigación en Neurooncología | 49 | 2012-02-01 | 2021-07-06 |
| Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO Dacomitinib, Doxycycline, Probiotic - Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Completed | Pfizer | 236 | 2011-12-26 | 2019-01-09 |
| PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma PF-00299804 - Head Neck Cancer Squamous Cell Metastatic, Head Neck Cancer Squamous Cell Recurrent | Phase 2 | Completed | Yonsei University | 49 | 2011-10-01 | 2014-09-30 |
| PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer PF00299804 - Advanced Gastric Cancer, HER2 | Phase 2 | Completed | Seoul National University Hospital | 28 | 2010-07-01 | 2015-11-20 |
| Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment PF-00299804 - Oral Cavity Cancer | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 13 | 2010-05-01 | 2015-07-10 |
Showing 20 of 26. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (10) · Brain Neoplasms (3) · Carcinoma, Squamous Cell (2) · Glioblastoma (2) · Head and Neck Neoplasms (2) · Neoplasm Metastasis (2) · Recurrence (2) · Carcinoma (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Mouth Neoplasms (1) · Neoplasms (1) · Penile Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Pfizer (8) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · National Cancer Centre, Singapore (2) · Shanghai Chest Hospital (2) · The Netherlands Cancer Institute (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · David Piccioni, M.D., Ph.D (1) · Fondazione Ricerca Traslazionale (1) · Grupo Español de Investigación en Neurooncología (1) · Guangdong Association of Clinical Trials (1) · Massachusetts General Hospital (1) · Samsung Medical Center (1) · Seoul National University Hospital (1) · University Health Network, Toronto (1) · Yonsei University (1)
South Korea (9) · United States (7) · Canada (3) · China (3) · Hong Kong (3) · Italy (3) · Singapore (3) · Japan (2) · Netherlands (2) · Spain (2) · Taiwan (2) · Australia (1) · Brazil (1) · Malaysia (1) · Poland (1)
Alessandro Morabito, MD (1) · Andrea Necchi, MD (1) · Boon Cher Goh (1) · Byoung Chul Cho, M.D.,Ph.D. (1) · Daniel SW Tan (1) · Daniel Tan, BSc, MBBS, PhD (1) · David Piccioni, M.D., Ph.D. (1) · E.E. Voest, prof. (1) · Lillian Siu, MD, FRCPC (1) · Ning Li, Doctor (1) · Paolo Bossi, MD (1)
PMID 24501009, PMID 25057165, PMID 25456362, PMID 25521398, PMID 25899785, PMID 26581547, PMID 26768165, PMID 29191595, PMID 31858327, PMID 32147669, PMID 34083331, PMID 35086719, PMID 35305596, PMID 35598186, PMID 36870947, PMID 37424386, PMID 38630551, PMID 40811939, PMID 41986720
2008 (1)